u DNA Plant Technology Corp., of Oakland, Calif., has signed a four- year research agreement with Panama-based Alida Marine Inc. to develop genetically engineered pineapples to control ripening and extend the shelf life of the fruit. Under the terms of the agreement, Alida has purchased 2 million shares of stock in DNA Plant Technology, which will have exclusive rights to the technology. u GenPharm International Inc., of Mountain View, Calif., has signed an agreement with Mollegaard Breeding and Research Centre, of Ejby, Denmark, to distribute the former's transgenic rat models in Europe. GenPharm's HLA-B27 transgenic rat is used as a model of human inflammatory disease. They are raised by inserting the human HLA- B27 gene into fertilized one-cell rat eggs, causing mature rats to develop lesions similar to those experienced in arthritis, psoriasis and inflammatory bowel disease. u Advanced Magnetics Inc., of Cambridge, Mass., has agreed to pay $1 million to Bristol-Myers Squibb, of New York, to regain marketing rights to the former's magnetic resonance imaging contrast agent. In addition to the $1 million, Advanced Magnetics will pay up to $2.75 million in royalties to Bristol-Myers Squibb, which will return a warrant for the purchase of 600,000 shares of Advanced Magnetics stock.
(c) 1997 American Health Consultants. All rights reserved.